In-depth Article
Marijuana to be Reclassified from a Schedule 1 to Schedule 3 Substance

President Trump’s Executive Order to Re-Classify Marijuana from a Schedule 1 to a Schedule 3 Substance.
Let’s Learn More About This Executive Order.

Marijuana has been classified as a Schedule 1 substance under the Controlled Substances Act (CSA) since 1970. Since 1970, there have been several attempts to reschedule Marijuana, but it appears that this latest effort will be the first successful attempt.

Now that Medical Marijuana has essentially been rescheduled, there is expected to be a renewed push to pass the Safer Banking Act.

The Secure And Fair Enforcement Regulation Banking Act (SAFER Banking Act) was introduced to provide financial institutions that serve state-legal cannabis businesses with a legal “safe harbor.”

In the same Executive order, President Trump also urges Congress to examine updating the definition of hemp to ensure that Full-spectrum CBD is accessible to patients.

This follows a controversial piece of legislation inserted into the November 2025 bill ending the government shutdown, banning almost all CBD products. 

Let’s take a deeper look at the reclassification of Marijuana and CBD, getting blindsided by Congress, including when both happened and the current state of both issues.

Trump Signs November Spending Bill That Ends the Government Shutdown, But Will Recriminalize Hemp Products with THC.

As reported in the November 5, 2025, issue of Marijuana Moment,

“Trump Signs Bill To Recriminalize Hemp THC Products, Years After Approving Their Legalization.”

Reported and written by Kyle Jaeger.

Mr.Jaeger reports that;

“President Donald Trump has signed a spending bill that includes provisions to ban most consumable hemp products.

“Following a historic, weeks-long government shutdown, the Senate approved the appropriations package on Monday to fund critical agencies. The House of Representatives followed suit on Wednesday, voting 222-209 to pass the bill.”

“Tucked inside the legislation is a controversial section to recriminalize hemp products containing THC that have proliferated since the crop was legalized under the 2018 Farm Bill that Trump signed during his first term in office. The president’s latest action reverses that move.”

(Tap or click to read the entire article.)

Trump Signs an Executive Order Reclassifying Medical Marijuana By Transferring It From Schedule I to Schedule III of the Controlled Substances Act, Part 1.

As reported in the December 18, 2025, issue of Marijuana Moment,

“Marijuana will be federally rescheduled under an executive order signed by President Donald Trump on Thursday December 18 2025.“

“Months after Trump said a decision on the cannabis reform proposal was imminent, the president issued the directive for agencies to begin moving forward with the plan to transfer cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA).

The directive also aims to address federal hemp laws to promote access to full-spectrum CBD that could be covered under federal health insurance plans.

The president emphasized that his order “doesn’t legalize marijuana in any way, shape or form, and in no way sanctions its use as a recreational drug.”

This marks one of the most significant developments in federal marijuana policy since its prohibition a half a century ago, with a Schedule III reclassification recognizing that marijuana has medical value and a lower abuse potential compared to other Schedule I drugs like heroin.”

(Tap or click to read the entire article.)

Trump Signs an Executive Order Reclassifying Medical Marijuana By Transferring It From Schedule I to Schedule III of the Controlled Substances Act, Part 2.

As reported in the December 18, 2025, issue of Marijuana Moment,

“The directive also aims to address federal hemp laws to promote access to full-spectrum CBD that could be covered under federal health insurance plans.”

Mr.Jaeger reports that;

“In addition to directing the attorney general to “take all necessary steps to complete the rulemaking process related to rescheduling marijuana to Schedule III of the CSA in the most expeditious manner in accordance with Federal law,”

Trump’s executive order also urges Congress to examine updating the definition of hemp to ensure that full-spectrum CBD is accessible to patients. If lawmakers do so, it could mitigate some concerns in the sector about a recent spending bill the president signed with provisions that would broadly ban consumable hemp products.”

A further redefinition of hemp would be part of a novel proposal to allow Medicare recipients to access non-intoxicating CBD that’d be covered under the federal health care plan.”

(Tap or click to read the entire article.)

Trump Signs an Executive Order Reclassifying Medical Marijuana By Transferring It From Schedule I to Schedule III of the Controlled Substances Act, Part 3.

On April 23, 2026, Medical Marijuana, under certain conditions, was reclassified as Schedule 3. Recreational Marijuana is still classified as Schedule 1.

Read these excerpts from an article for a deeper understanding of the rescheduling of Medical Marijuana. 

As reported in the April 23, 2026, issue of Marijuana Moment. Reported and written by Tom Angell. 

Federal Marijuana Rescheduling Announced By Department Of Justice, Months After Trump Executive Order.

“Acting Attorney General Todd Blanche on Thursday announced that rescheduling is finally happening. The process will happen in phases, DOJ said.

Under an order signed by Blanche, marijuana products regulated by a state medical cannabis license will immediately move to Schedule III, as will any marijuana products that are approved by the Food and Drug Administration (FDA).

Then, beginning on June 29, there will be a new expedited administrative hearing process to consider the broader rescheduling of cannabis from Schedule I to Schedule III. The Federal Register filing on the hearing says it “will conclude not later than July 15.”

Marijuana to be ReClassified from a Schedule 1 to Schedule 3 Substance, Some Science, Part 1

This is an exciting and promising development, but it raises questions and concerns. Here are excerpts from a December 23, 2025, post written by Lindsey Leake and published on the NBC News Website.

“Cannabis reclassification could ‘open the floodgates’ for research, scientists say. “

Various scientists believe that reclassifying Marijuana (AKA “Cannabis”) could lead to dramatic increases in research opportunities. 

“A long-awaited change in drug policy could bring scientists one step closer to understanding the harms and benefits of marijuana, the most commonly used federally illegal substance.”

“Decades of federal drug control policy have neglected marijuana’s medical uses,” the order says. “That oversight has limited the ability of scientists and manufacturers to complete the necessary research on safety and efficacy to inform doctors and patients.”

Ms. Leake continues; 

“While the reclassification is intended to bolster medical marijuana research and won’t legalize cannabis at the federal level, the move comes at a time when use in the United States is at a high.”

Marijuana to be ReClassified from a Schedule 1 to Schedule 3 Substance, Some Science, Part 2

Gallup data from 2023 and 2024 estimates that 15% of adults smoke Marijuana, up from 7% in 2013.

Medical Marijuana is typically prescribed to ease chronic pain; control nausea and vomiting, often in people receiving chemotherapy for cancer; and bring about an appetite in people with certain medical conditions.

Scientists like Ziva Cooper are hopeful the reclassification could revolutionize public health through more comprehensive Marijuana research.

“It is extremely difficult to study cannabis, aka marijuana, for both the potential adverse effects as well as therapeutic effects,” said Cooper, director of the Center for Cannabis and Cannabinoids at the University of California, Los Angeles. “The industry is developing at a very fast pace, and so consumer behavior is developing along with that industry.

“It’s very hard for us, as scientists, as people who are interested in public health, to be able to keep up with the changes, in part because the research is difficult.”

Despite working in a cannabis-friendly state, Cooper said she faces the same research hurdles as her peers in states such as Idaho, where no Marijuana use is permitted whatsoever.

Marijuana to be ReClassified from a Schedule 1 to Schedule 3 Substance, Some Science, Part 3

“Last year, the National Institutes of Health awarded $75 million to therapeutic cannabinoid research, up from $70 million in 2023. Additionally, $217 million went to cannabinoids, or cannabis compounds, and $53 million went to cannabidiol, or CBD, a nonpsychoactive cannabinoid.”

“Medical marijuana is typically prescribed to ease chronic pain; control nausea and vomiting, often in people receiving chemotherapy for cancer; and bring about an appetite in people with certain medical conditions. It’s unclear whether rescheduling cannabis will affect funding for recreational marijuana research.

However, administrative red tape means cannabis studies are often observational, compared with the rigorous clinical trials required of pharmaceutical research, said Dr. Brooke Worster, medical director of the M.S. in medical cannabis science and business program at Thomas Jefferson University in Philadelphia. Their findings have been mixed.”

“Research published this year in the journal Biomedicines suggested cannabinoids are a “promising” alternative to opioids for chronic pain management but cited an urgent need for large-scale, randomized controlled trials.”

(Tap or click to read the entire post by Ms. Leake.)

Groovy Hemp Company Marijuana to be ReClassified from a Schedule 1 to Schedule 3 Substance FAQs

Groovy Hemp Company CBD Learning Center

Groovy Hemp Company provides a free information hub for people who would like to learn more about hemp-based products. That includes; YouTube videos, In-Depth Articles, FAQs, and a Glossary. 

Groovy Hemp Company provides a specific page with a collection of CBD-focused YouTube videos. Tap or click to visit our CBD YouTube page.

Or, you can tap or click Groovy Hemp Company YouTube Channel and subscribe. Many thanks!

And please take a few moments to stop by the recently relaunched Groovy Hemp Podcast Page. You can also find Groovy Hemp Podcast on many podcast channels, including:

Apple Podcasts, Spotify, SoundCloud, iHeart Radio, Podchaser, Radio Public, Patreon, Amazon Music Podcasts, Pandora, and Deezer.

Our Google Web Stories help you learn more about how CBD Oil, CBG Oil, and CBDA Oil may reduce inflammation and encourage workout recovery after a tough day in the fitness center. They could also manage chronic stressors.

You can also learn how CBD oil might help you get quality sleep. Tap or click to experience our very Groovy Google Web Stories.

Marijuana to be ReClassified from a Schedule 1 to Schedule 3 Substance, The Big Wrap-up

As always, our goal is to educate the CBD Oil consumer so they can make better-informed buying decisions.

If you can’t find your answer on a CBD-related issue there, our email address is robb [at] groovyhempcompany [dot] com, or Tap or click to email us right now. We will respond within 24 hours.

Please don’t ask us for medical advice. We will just suggest you contact your physician.

Groovy Hemp Company is your CBD Online Marketplace. It is where to buy the best CBD Oil Products, Order Today!

Thank you for stopping by and reading DEA Classifying THC-O Products as Schedule 1 Substances.  Happy Trails!

Tap or click to read more Groovy Hemp Company In-depth Articles.